BIOMAT Database Logo BIOMAT Database Logo

[The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation]. 1990

M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Department of Urology, Kinki University School of Medicine.

There has been no useful treatments for chronic vascular rejection (CVR) after kidney transplantation until now. Recently, however, some reports have suggested that the thromboxane A2 synthetase inhibitor, OKY-046, is useful in reducing proteinuria in nephrotic syndrome and preventing progression of CVR. Five patients with CVR (serum creatinine range: 1.7-2.6 mg/dl) were treated with OKY-046 for over one year and the effect of OKY-046 was evaluated. One patient developed acute rejection and another renal hypertension during this study. Except for the cases of acute rejection and renal hypertension, serum creatinine slightly decreased in 1 case and remained unchanged in 2 cases. Urinary excretion of protein and thromboxane B2 decreased significantly but prostaglandin E2 did not change in the treatment of the deterioration with OKY-046. We concluded that OKY-046 was effective in preventing graft function and decreasing urinary protein excretion in kidney transplant recipients with CVR.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008689 Methacrylates Acrylic acids or acrylates which are substituted in the C-2 position with a methyl group. Methacrylate
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000179 Acrylates Derivatives of acrylic acid (the structural formula CH2

Related Publications

M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Application of prostacyclin analogue and thromboxane synthetase inhibitor to chronic vascular rejection after kidney transplantation.
October 1987, Transplantation proceedings,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Controlled prospective study of treatment for chronic rejection after kidney transplantation by thromboxane synthetase inhibitor.
April 1993, Transplantation proceedings,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Effect of prostaglandin I2 analogue and thromboxane A2 synthetase inhibitor on chronic rejection in rats.
January 1997, Transplantation proceedings,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
[Thromboxane A2 metabolism and clinical effects of selective thromboxane A2 synthetase inhibitor in patients with chronic glomerulonephritis].
June 1987, Nihon Jinzo Gakkai shi,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Thromboxane A2 in preservation-reperfusion injury: the effect of thromboxane A2 synthetase inhibitor.
May 1996, The Journal of surgical research,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046.
June 1986, Experientia,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Effects of thromboxane A2 synthetase inhibitor on postischemic liver injury in rats.
January 1991, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
Effects of a selective thromboxane A2 synthetase inhibitor on immune complex glomerulonephritis.
January 1984, Nephron,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
[Thromboxane A2 synthetase inhibitor in asthma therapy].
November 1996, Nihon rinsho. Japanese journal of clinical medicine,
M Imanishi, and M Ikegami, and T Nishioka, and T Ishii, and T Uemura, and S Kunikata, and H Kanda, and T Matsuura, and T Akiyama, and T Kurita
[Chronic arterial occlusive diseases--drug therapy and thromboxane A2 synthetase inhibitor].
September 1991, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!